Stage IV Bladder Cancer AJCC v8 Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0109735 (Stage IV Bladder Cancer AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTreatment